1-O-Octadecyl-2-O-acetyl-sn-glycero-3-phosphocholine
CAS: 74389-69-8
Ref. 3D-FO111145
25mg | 329,00 € | ||
50mg | 478,00 € | ||
100mg | 791,00 € | ||
250mg | 1.486,00 € | ||
500mg | 2.592,00 € |
Información del producto
- PAF (C??)
- (2R)-2-(acetyloxy)-3-(octadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate
- (R)-2-Acetoxy-3-(octadecyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
- 1-O-Octadecyl-2-O-acetyl-sn-glycerol-3-phosphorylcholine
- 1-O-Octadecyl-2-acetyl-sn-glycero-3-phosphocholine
- 1-O-Octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine
- 1-O-Octadecyl-platelet-activating factor
- 1-O-Stearyl-2-acetyl-sn-glyceryl-3-phosphorylcholine
- 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R)-
- 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (R)-
- Ver más sinónimos
- Blood platelet activating factor-acether
- Blood platelet-activating factor
- C<sub>18</sub>-PAF
- C<sub>18</sub>-PAF-acether
- PAF acether
- Platelet activating factor-acether
- Platelet-activating factor
- Platelet-activating factor (1-O-octadecyl)
- Ro 14-8161
1-O-Octadecyl-2-O-acetyl-sn-glycero-3-phosphocholine (OGPC) is a phospholipid that has been shown to be an effective drug in the treatment of chronic arthritis. It is a potent antagonist of the inflammatory response, and has been shown to inhibit the production of inflammatory cytokines such as tumour necrosis factor alpha (TNFα). OGPC has been used in cell culture studies, which have shown that it inhibits IL2 receptor binding and TNFα release by human monocytes. Clinical studies have also shown that OGPC can be used to treat arthritis.
Propiedades químicas
Consulta técnica sobre: 3D-FO111145 1-O-Octadecyl-2-O-acetyl-sn-glycero-3-phosphocholine
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.